바이오시스

비상장계속사업자

BIOSIS CO.,LTD.

심광보

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

바이오시스

Business Reg. No. 6178131635 · CEO 심광보

I.Investment Overview

Target바이오시스 (6178131635)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명바이오시스
영문명BIOSIS CO.,LTD.
대표자심광보
사업자등록번호6178131635
법인등록번호1801110345371
설립일2000.12.14

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1,748.120211,810.120221,95120232,019.420242,126.62025
영업이익100M KRW30.7202137.7202234.4202324.3202425.22025
순이익100M KRW28.8202125.8202237.1202322202433.92025
Item20252024202320222021
자산총계370.4억원328.7억원310.4억원274.9억원285.6억원
부채총계43억원35.3억원39억원43.9억원80.5억원
자본총계327.3억원293.4억원271.4억원231억원205.1억원
매출액2,126.6억원2,019.4억원1,951억원1,810.1억원1,748.1억원
영업이익25.2억원24.3억원34.4억원37.7억원30.7억원
순이익33.9억원22억원37.1억원25.8억원28.8억원

VI.Financial Ratios

FY2025 basis

1.18%

영업이익률

1.6%

순이익률

9.16%

ROA

10.37%

ROE

13.15%

부채비율

88.38%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

바이오시스 투심보고서 | Alpha Lenz